In news that we should all celebrate before some big drug company buys it up and locks it away, a promising new cancer vaccine is set to begin human trials after having close to a 100% success rate in mice.

The study, which is taking place at Stanford University will test out the new treatment on 35 people suffering from Lymphoma later this year. The initial trial in mice was able to eliminate tumors in 87 out of 90 mice, all of which suffered from various kinds of cancer, including lymphoma, breast cancer, and colon cancer and was even proven to be successful after the cancer had metastasized.

The treatment protocol works by injecting 2 agents directly into the tumor, stimulating the production f T cells. Unfortunately, the tests will only be on lymphoma, so there will have to be a lot more trials before it hits the market.